Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2018-01-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable malignant bowel obstruction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Small Bowel Evaluation Using Novel Motorized Spiral Enteroscopy

NCT04959994

Small Bowel Disease

UNKNOWN

A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea

NCT01234168

Neuroendocrine Tumors Carcinoid Syndrome

COMPLETED

Novel Motorized Spiral Enteroscopy Vs Single Balloon Enteroscopy In Patients With Small Bowel Disorders- A RCT

NCT05548140

Small Bowel Disease

COMPLETED NA

Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy

NCT01324284

Colorectal Carcinoma

COMPLETED PHASE3

Comparison of Using Regular or Rotary Polypectomy Snare for the Resection of Colorectal Polyps

NCT03608930

Polypectomy Snare

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intestinal Obstruction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard care and Lanreotide Autogel

Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.

Group Type EXPERIMENTAL

lanreotide (Autogel formulation)

Intervention Type DRUG

Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.

Standard care

Standard care according to site clinical practice.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lanreotide (Autogel formulation)

Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must demonstrate willingness to participate in the study and to be compliant with any protocol procedure.
* Provision of written informed consent prior to any study related procedure.
* Diagnosis of an inoperable malignant bowel obstruction, confirmed by appropriate imaging report.
* In case of peritoneal carcinomatosis, diagnostic confirmation by CT or MRI scan.
* Confirmed as inoperable after medical advice.
* Patient with a nasogastric tube or presenting with 3 or more episodes of vomiting every day in the last consecutive 48 hours.
* Patient life expectancy must be more than 14 days.

Exclusion Criteria

* Has operable obstruction or any sub-obstruction.
* Has bowel obstruction due to a non-malignant cause; (hypokaliaemia, drug side-effects, renal insufficiency, etc).
* Has signs of bowel perforation.
* Has prior treatment with somatostatin or any analogue within the previous 60 days.
* Has a known hypersensitivity to any of the study treatments or related compounds.
* Is likely to require treatment during the study with somatostatin or any analogue other than the study treatment.
* Is at risk of pregnancy or lactation, or is likely to father a child during the study. Females of childbearing potential must provide a negative pregnancy test at start of study and must be using oral or double barrier contraception. Non childbearing potential is defined as post-menopause for at least 1 year, surgical sterilisation or hysterectomy at least three months before the start of the study.
* Has any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
* Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No